Medilink Therapeutics
Suzhou
About Medilink Therapeutics
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $120.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2022)
- Website: medilinkthera.com
Industries & Categories
Biotechnology, Genetics, Therapeutics
Canonical: https://fsome.com/organization/medilink-therapeutics-6008 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.